
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 14pt">SECURITIES AND EXCHANGE COMMISSION

<P align="center" style="font-size: 12pt">Washington, D.C. 20549

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 12pt"><B>CURRENT REPORT</B>



<P align="center" style="font-size: 10pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>


<P align="left" style="font-size: 10pt">Date of Report (date of earliest event reported): December&nbsp;24, 2004.



<P align="center" style="font-size: 10pt"><B>BioTime, Inc.</B>


<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>1-12830</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>94-3127919</B></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>935 Pardee Street<BR>
Berkeley, California 94710</B>


<DIV align="center" style="font-size: 10pt">(Address of principal executive offices)</DIV>



<P align="center" style="font-size: 10pt"><B>(510)&nbsp;845-9535</B>


<DIV align="center" style="font-size: 10pt">(Registrant&#146;s telephone number, including area code)</DIV>


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17
CFR 230.425)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR
240.14a-12)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
  Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;&nbsp;&nbsp;&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;1.01 Entry Into a Material Definitive Agreement</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002"> SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="f04328exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>







<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Statements made in this Report that are not historical facts may
constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Such risks and uncertainties include but are not limited to those
discussed in this report and in BioTime&#146;s Annual Report on </I><I>Form 10-K</I><I> filed with
the Securities and Exchange Commission. Words such as &#147;expects,&#148; &#147;may,&#148; &#147;will,&#148;
&#147;anticipates,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; and
similar expressions identify forward-looking statements.</I>


<P align="left" style="font-size: 10pt"><B>Section&nbsp;1-Registrant&#146;s Business Operations</B>


<!-- link1 "Item&nbsp;1.01 Entry Into a Material Definitive Agreement" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;1.01 Entry Into a Material Definitive Agreement</B>


<P align="left" style="font-size: 10pt">On December&nbsp;24, 2004, BioTime, Inc. and Summit Pharmaceuticals International
Corporation (&#147;Summit&#148;) entered into an agreement to develop Hextend and
PentaLyte for the Japanese market. Hextend and PentaLyte are physiologically
balanced blood plasma volume expanders designed for the treatment of
hypovolemia. Hypovolemia is a condition caused by low blood volume, often from
blood loss during surgery or from injury. Plasma volume expanders maintain
circulatory system fluid volume and blood pressure and keep vital organs
perfused during surgery. Hextend and PentaLyte are similar formulations,
except that PentaLyte contains a lower molecular weight hydroxyethyl starch
than Hextend, and is more quickly metabolized. PentaLyte is designed for use
when shorter lasting volume expansion is desirable.


<P align="left" style="font-size: 10pt">Under the terms of the agreement, Summit will apply for regulatory approval to
manufacture and market Hextend and PentaLyte in Japan for use at body
temperatures above 12 Centigrade. Summit will begin by preparing a development
plan for Hextend. Summit will fund all laboratory, preclinical and clinical
testing and developmental activities regarding the products, and will pay all
application filing and similar fees for purposes of obtaining and maintaining
regulatory approvals in Japan. Summit will not be obligated to begin to seek
regulatory approval for PentaLyte until BioTime completes its Phase II clinical
trial of PentaLyte in the United States and makes the results available to
Summit. BioTime&#146;s Phase II clinical trial is now beginning and will take place
at Duke University Medical Center.


<P align="left" style="font-size: 10pt">Under the Agreement, Summit will make the following payments to BioTime:



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$300,000 within ten days after execution of the agreement;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$450,000 by April&nbsp;15, 2005; and</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$150,000 by October&nbsp;31, 2005.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>

<P align="left" style="font-size: 10pt">A portion of the cash payments will be a partial reimbursement of BioTime&#146;s
development costs of Hextend and a portion will be a partial reimbursement of
BioTime&#146;s development costs of PentaLyte.


<P align="left" style="font-size: 10pt">Within ten days after BioTime approves Summit&#146;s development plan for Hextend,
BioTime will pay Summit a one-time fee of $130,000 for Summit&#146;s services in
preparing the development plan.


<P align="left" style="font-size: 10pt">BioTime and Summit do not plan to manufacture and market Hextend and PentaLyte
themselves. Instead, they will seek to license manufacturing and marketing
rights to a third party such as a pharmaceutical company.


<P align="left" style="font-size: 10pt">When Hextend and PentaLyte are licensed and sold in Japan, the revenues from
licensing fees, royalties, and net sales, and any other payments made for
co-development, manufacturing, or marking rights, will be shared between
BioTime and Summit as follows: 40% to BioTime and 60% to Summit. Net sales
means the gross revenues from the sale of a product, less rebates, discounts,
returns, transportation costs, sales taxes and import/export duties.


<P align="left" style="font-size: 10pt">BioTime will pay to Summit 8% of all net royalties actually received by BioTime
from the sale of PentaLyte in the United States plus 8% of any license fees
that BioTime receives in consideration of granting a license to develop,
manufacture and market PentaLyte in the United States. Net royalties means
royalty payments received during a calendar year, minus the following costs and
expenses incurred during such calendar year: (a)&nbsp;all taxes assessed (other than
taxes determined with reference to BioTime net income) and credits given or
owed by BioTime in connection with the receipt of royalties on the sale of
PentaLyte in the United States, and (b)&nbsp;all fees and expenses payable by
BioTime to the United States Food and Drug Administration (directly or as a
reimbursement of any licensee) with respect to PentaLyte. In the case of
license fees received from Hospira, Inc. based upon the combined sale of
PentaLyte and Hextend, the portion of such license fee that will be deemed to
be paid on account of the sale of PentaLyte will be determined by multiplying
the total license fee paid by a fraction, the numerator of which will be the
total net sales of PentaLyte in the United States for the applicable period and
the denominator of which shall be the total net sales of Hextend and PentaLyte
in the United States for the same period.


<P align="left" style="font-size: 10pt">Either BioTime or Summit may terminate the agreement as follows:



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By giving to the other party 60&nbsp;days prior written notice
following the bankruptcy or the insolvency of the other party; or</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the breach of any material provision of the agreement by
the other party if the breach is not cured within 60&nbsp;days after
written notice thereof to the party in default.</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt">BioTime may terminate the agreement upon 60&nbsp;days prior written notice at any
time following Summit&#146;s failure to use diligent efforts to achieve any one of

the following milestones: (A)
submitting to BioTime for approval a development plan that is substantially
complete in all material respects within six months after the signing of the
agreement, (B)&nbsp;initiating and conducting to



<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">completion clinical studies needed
for regulatory approval of either Hextend or PentaLyte in accordance with the
timetable included in the development plan approved by BioTime; or (C)
obtaining regulatory approval of either Hextend or PentaLyte after the clinical
studies are complete.


<P align="left" style="font-size: 10pt">Summit may terminate the agreement at any time upon ninety 90&nbsp;days prior
written notice to BioTime if Summit determines that it no longer wishes to
pursue obtaining regulatory approval of Hextend and PentaLyte.


<P align="left" style="font-size: 10pt">If BioTime becomes bankrupt or insolvent or breaches a material provision of
the agreement such that Summit would have the right to terminate the agreement,
Summit may elect to keep the agreement in effect, and in lieu of any other
remedy that Summit might have (1)&nbsp;if any of the cash installment payments are
not yet payable Summit will be exempted from making those payments, and (2)
BioTime&#146;s 40% share of revenues will be reduced to 20%.


<P align="left" style="font-size: 10pt">The preceding discussion of the agreement is a summary only, does not purport
to describe in full all provisions of the agreement, and is qualified in all
respects by the full text of the agreement, a copy of which has been filed as
an exhibit to this report and which is incorporated by reference herein.


<P align="left" style="font-size: 10pt">Hextend&#174; and PentaLyte&#174; are registered trademarks of BioTime, Inc.



<P align="left" style="font-size: 10pt"><B>Section&nbsp;9-Financial Statements and Exhibits</B>


<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 8pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Exhibit<BR>
Numbers</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><B>Description</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><HR size="1" noshade><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hextend and PentaLyte Collaboration Agreement Between
BioTime, Inc. and Summit Pharmaceuticals International
Corporation</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 " SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3"><B>BIOTIME, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>Date: December 30, 2004&nbsp;</TD>
    <TD align="left">By</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000">&nbsp;/s/ Steven Seinberg
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Steven Seinberg,&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">5
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 8pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Exhibit<BR>
Numbers</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><B>Description</B></TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><HR size="1" noshade><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hextend and PentaLyte Collaboration Agreement Between
BioTime, Inc. and Summit Pharmaceuticals International
Corporation</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">6
</DIV>
</BODY>
</HTML>

